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(degree and duration of gluten restric-
tion or dapsone/sulfapyridine dose);
however, future studies should attempt
to correlate levels of IgA anti-eTG with
parameters of disease activity, includ-
ing degree and duration of gluten
restriction, and dapsone/sulfapyridine
dose. The patient presented in Table 2
shows that the levels of each Ab assay
decreases over time with adherence to a
gluten-free diet. Although definitive con-
clusions cannot be made from one
patient, these results suggest that the
levels of IgA against eTG correlate with
dietary gluten intake. Prospective studies
should be designed to evaluate the levels
of IgA anti-eTG in DH patients over time
after initiation of a gluten-free diet.
IgA anti-eTG was present in only
11.1% of pediatric CD, which is
significantly lower than that reported
in adult CD (B50%) (Hull et al., 2008).
These results are similar to our pre-
viously published data showing a low
prevalence of IgA anti-eTG in pediatric
CD patients. This occurred in the
setting of significantly elevated concen-
trations of IgA anti-tTG (90.7%). The
majority of the six pediatric CD patients
with IgA anti-eTGþ results showed low
titers (13, 13, 14, 15, 20, and 96 Units)
and all were duodenal biopsy positive
(1 of 18 Marsh 3a (5.6%), 1 of 15 Marsh
3b (6.7%), and 4 of 16 Marsh 3c
(25.0%)). All six pediatric CD patients
were also positive for IgA anti-tTG (6 of
6), for IgA anti-deamidated gliadin
peptides (6 of 6), and for IgG anti-
deamidated gliadin peptides (5 of 6).
We will follow-up pediatric CD
patients with IgA anti-eTGþ results to
find out whether they develop symp-
toms of DH.
In conclusion, IgA anti-eTG was
more sensitive in detecting DH
than any other marker associated with
gluten-sensitive enteropathy and its
prevalence is significantly lower in
pediatric CD than that which has
been reported in adult CD. In a
patient suspected of having DH, the
present data support testing for IgA
anti-eTG, which may help in screening
and monitoring the response to a
gluten-free diet. We then recommend
a biopsy of uninvolved, perilesional
skin in an area of grouped vesicles or
erosions for direct immunofluores-
cence, which is the gold standard for
diagnosis.
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TO THE EDITOR
Lentigo simplex (LS) is a benign skin
lesion preferentially observed in young-
er people, although it may occur at any
age. The lesion measures a few milli-
meters in diameter, is brown to black,
and is clinically indistinguishable from
a melanocytic nevus. Histopathologi-
cally, LS shows a moderate elongation
of the epidermal rete ridges and basal
hyperpigmentation. The number of
melanocytes in the basal epidermal
layer may be slightly increased. In
contrast to LS, solar lentigo displays
markedly elongated rete ridges and
profound actinic elastosis in the dermis.
It has been proposed that LS mayAbbreviations: LS, lentigo simplex
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evolve into a lentiginous/junctional
melanocytic nevus when melanocytes
start proliferating and aggregating to
form small nests in the junctional zone,
whereas solar lentigo may be a pre-
cursor lesion of seborrheic keratosis
(Ackerman and Ragaz, 1984). In the
past few years, it has become well
known that melanocytic nevi frequently
show the BRAF V600E hotspot mutation
(Pollock et al., 2003). The genetic basis
of LS, however, remains unknown.
To investigate a possible common
genetic background of LS and melano-
cytic nevi, we analyzed both LS and
melanocytic nevi for the BRAF V600E
mutation. We retrieved 58 LS samples
(from 30 males, 28 females; mean age
34.6 years) and 46 melanocytic nevi
(from 21 males, 25 females; mean age
38.7 years) from the histological files of
the Department of Dermatology at the
University of Regensburg, Germany.
The characteristics of the patients and
lesions are shown in Table 1. Written,
informed consent was obtained from all
patients according to the guidelines of
the local ethics committee and the
Declaration of Helsinki, and the study
was approved by the ethics committee
of the University Clinic of Regensburg.
The samples were manually micro-
dissected from formalin-fixed paraffin-
embedded material, and DNA was
isolated using standard protocols. For
the analysis of the BRAF V600E hotspot
mutation, a highly sensitive allele-spe-
cific PCR (PCR amplification of specific
alleles, PASA) was used as described
previously (Stoehr et al., 2004). None
of the 58 LS specimens exhibited
the BRAF V600E mutation (Table 1,
Figure 1a). The HT29 colon carcinoma
cell line with a known BRAF V600E
mutation was used as a positive control
Table 1. Analysis of BRAF, FGFR3, and PIK3CA in lentigo simplex and melanocytic nevus
No. Sex Age Diagnosis BRAF FGFR3 PIK3CA
1 f 34 Lentigo simplex wt wt wt
2 f 28 Lentigo simplex wt wt wt
3 f 55 Lentigo simplex wt wt wt
4 m 23 Lentigo simplex wt wt wt
5 f 33 Lentigo simplex wt wt wt
6 f 35 Lentigo simplex wt wt wt
7 f 45 Lentigo simplex wt wt wt
8 m 16 Lentigo simplex wt wt wt
9 m 18 Lentigo simplex wt wt wt
10 m 15 Lentigo simplex wt wt wt
11 m 40 Lentigo simplex wt wt wt
12 m 17 Lentigo simplex wt wt na
13 f 27 Lentigo simplex wt wt wt
14 m 29 Lentigo simplex wt wt wt
15 f 38 Lentigo simplex wt wt na
16 m 39 Lentigo simplex wt wt wt
17 f 35 Lentigo simplex wt wt wt
18 f 21 Lentigo simplex wt wt wt
19 f 32 Lentigo simplex wt wt wt
20 f 72 Lentigo simplex wt wt wt
21 m 38 Lentigo simplex wt wt wt
22 f 27 Lentigo simplex wt wt na
23 f 42 Lentigo simplex wt wt na
24 m 30 Lentigo simplex wt wt na
25 m 56 Lentigo simplex wt wt wt
26 f 42 Lentigo simplex wt wt wt
27 m 22 Lentigo simplex wt wt na
28 m 19 Lentigo simplex wt wt wt
29 m 35 Lentigo simplex wt wt na
30 f 28 Lentigo simplex wt wt na
Table 1 Continued on the following page
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Table 1. Continued
No. Sex Age Diagnosis BRAF FGFR3 PIK3CA
31 m 24 Lentigo simplex wt wt na
32 f 24 Lentigo simplex wt wt wt
33 m 25 Lentigo simplex wt wt na
34 m 52 Lentigo simplex wt wt wt
35 m 51 Lentigo simplex wt wt wt
36 f 23 Lentigo simplex wt wt wt
37 m 26 Lentigo simplex wt wt wt
38 m 43 Lentigo simplex wt wt wt
39 f 40 Lentigo simplex wt wt wt
40 f 60 Lentigo simplex wt wt wt
41 m 62 Lentigo simplex wt wt na
42 m 21 Lentigo simplex wt wt wt
43 m 14 Lentigo simplex wt wt wt
44 m 75 Lentigo simplex wt wt wt
45 f 44 Lentigo simplex wt wt wt
46 m 42 Lentigo simplex wt wt wt
47 f 23 Lentigo simplex wt wt wt
48 f 37 Lentigo simplex wt wt wt
49 f 40 Lentigo simplex wt wt wt
50 m 34 Lentigo simplex wt wt wt
51 m 27 Lentigo simplex wt wt wt
52 f 12 Lentigo simplex wt wt wt
53 m 39 Lentigo simplex wt wt wt
54 m 36 Lentigo simplex wt wt wt
55 f 32 Lentigo simplex wt wt wt
56 f 22 Lentigo simplex wt wt wt
57 f 60 Lentigo simplex wt wt wt
58 m 30 Lentigo simplex wt wt wt
1 m 51 Lentiginous melanocytic nevus wt wt wt
2 m 43 Lentiginous melanocytic nevus wt wt wt
3 m 67 Lentiginous melanocytic nevus wt wt wt
4 m 39 Lentiginous melanocytic nevus wt wt wt
5 m 28 Lentiginous melanocytic nevus wt wt wt
6 f 17 Lentiginous melanocytic nevus wt wt wt
7 m 65 Lentiginous melanocytic nevus V600E wt wt
8 f 29 Lentiginous melanocytic nevus V600E wt wt
9 m 31 Lentiginous melanocytic nevus wt wt wt
10 m 58 Junctional melanocytic nevus wt wt wt
11 f 24 Junctional melanocytic nevus wt wt wt
12 m 43 Junctional melanocytic nevus wt wt wt
13 m 48 Compound melanocytic nevus wt wt wt
14 f 60 Compound melanocytic nevus wt wt wt
15 f 12 Compound melanocytic nevus V600E wt wt
Table 1 Continued on the following page
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to exclude false-negative results.
Furthermore, we screened 46 melano-
cytic nevi (9 lentiginous, 3 junctional, 11
compound, and 23 dermal nevi) for the
BRAF hotspot mutation, which could be
detected in 26/46 (57%) of the nevi.
Interestingly, the V600E mutation was
present in only 17% of the lentiginous/
junctional nevi, whereas 55% of the
compound nevi and 78% of the dermal
nevi revealed this hotspot mutation
(Figure 1b). The difference in the BRAF
V600E mutation frequency between LS
and melanocytic nevi was highly signifi-
cant (Po0.001; Fisher’s exact test).
Because most of the patients in the
investigated cohort originated from south-
eastern Germany, we cannot exclude
the possibility that a different genetic
population would show varying results.
Because solar lentigos and sebor-
rheic keratoses display FGFR3 and
PIK3CA mutations (Hafner et al.,
2007, 2009), we also analyzed these
genes in LS lesions and melanocytic
nevi. FGFR3 mutations were analyzed
using a multiplex SNaPshot (Applied
Biosystems, Foster City, CA) assay
covering 11 point mutations (R248C,
S249C, G372C, S373C, Y375C, G382R,
A393E, K652E, K652M, K652Q, and
K652T) that had previously been de-
scribed in skin tumors (Hafner et al.,
2006). For the detection of four PIK3CA
hotspot mutations (E542K, E545K,
E545G, and H1047R), a recently devel-
oped PIK3CA SNaPshot assay was used
(Hurst et al., 2009). None of the 58 LS
lesions or the 46 melanocytic nevi
displayed an FGFR3 or a PIK3CA point
mutation (Table 1).
Our results indicate that the BRAF
V600E hotspot mutation is not involved
in the pathogenesis of LS. In contrast,
33% of PUVA (psoralen plus UVA)
Table 1. Continued
No. Sex Age Diagnosis BRAF FGFR3 PIK3CA
16 f 60 Compound melanocytic nevus V600E wt wt
17 m 42 Compound melanocytic nevus wt wt wt
18 f 26 Compound melanocytic nevus wt wt wt
19 f 52 Compound melanocytic nevus V600E wt wt
20 m 23 Compound melanocytic nevus V600E wt wt
21 f 35 Compound melanocytic nevus V600E wt wt
22 m 32 Compound melanocytic nevus wt wt wt
23 f 22 Compound melanocytic nevus V600E wt wt
24 m 34 Dermal melanocytic nevus V600E wt wt
25 f 36 Dermal melanocytic nevus V600E wt wt
26 f 10 Dermal melanocytic nevus V600E wt wt
27 f 73 Dermal melanocytic nevus V600E wt wt
28 f 56 Dermal melanocytic nevus V600E wt wt
29 m 54 Dermal melanocytic nevus wt wt wt
30 f 56 Dermal melanocytic nevus V600E wt wt
31 m 26 Dermal melanocytic nevus V600E wt wt
32 m 48 Dermal melanocytic nevus V600E wt wt
33 f 24 Dermal melanocytic nevus V600E wt wt
34 f 19 Dermal melanocytic nevus V600E wt wt
35 f 29 Dermal melanocytic nevus V600E wt wt
36 f 12 Dermal melanocytic nevus V600E wt wt
37 m 36 Dermal melanocytic nevus V600E wt wt
38 f 16 Dermal melanocytic nevus wt wt wt
39 m 64 Dermal melanocytic nevus V600E wt wt
40 m 36 Dermal melanocytic nevus V600E wt wt
41 f 47 Dermal melanocytic nevus V600E wt wt
42 f 45 Dermal melanocytic nevus V600E wt wt
43 f 13 Dermal melanocytic nevus wt wt wt
44 f 52 Dermal melanocytic nevus V600E wt wt
45 m 46 Dermal melanocytic nevus wt wt wt
46 f 40 Dermal melanocytic nevus wt wt wt
m, male; f, female; wt, wild-type; na, not available.
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lentigines showed this mutation in a
previous report (Lassacher et al., 2006).
Melanocytic nevi harbor BRAF muta-
tions very frequently, with a reported
range of 20–80% (Thomas, 2006). In
our study, the BRAF V600E mutation
was present in 57% of the melanocytic
nevi. BRAF mutations are thought to
stimulate the proliferation of melano-
cytes in nevi and melanomas. It has
been proposed that a further prolifera-
tion of the melanocytes in LS may result
in the formation of melanocytic cell
nests and subsequently in a lentiginous
or junctional melanocytic nevus. In this
case, LS would represent a precursor
lesion of melanocytic nevi (Ackerman
and Ragaz, 1984). However, we found
no BRAF V600E mutations in LS,
indicating that this benign lesion does
not share a common genetic back-
ground with melanocytic nevus. This
finding could be explained in two
ways: (i) LS is not a precursor lesion of
melanocytic nevus and instead repre-
sents an independent benign skin
tumor or (ii) LS is a precursor lesion of
melanocytic nevus, but the BRAF
V600E mutations occur late in this
lentigo–nevus sequence. The latter
would be congruent with the observed
trend in this study that the frequency of
BRAF V600E mutations increased from
lentiginous/junctional nevi to com-
pound and dermal nevi, implying that
BRAF mutations occur during the pro-
posed progression from junctional to
compound and dermal nevus rather
than from LS to junctional nevus.
However, the differences between the
types of melanocytic nevi were not
statistically significant, which may be
attributable to the small sampling size
of the melanocytic nevus subgroups.
LS must also be discriminated from
solar lentigo. We analyzed a possible
common pathogenetic background of
both lesions. Although solar lentigos
display FGFR3 and PIK3CA mutations
and therefore share a common genetic
basis with seborrheic keratoses, the LS
in our study did not show any of these
mutations. There has been a report of
an H1047R PIK3CA mutation in one
LS sample, which was included in a
large mutation profiling study of various
tumors (Thomas et al., 2007). This
H1047R mutation was also covered by
the PIK3CA SNaPshot assay used in our
study, but we could not detect any
PIK3CA mutations in LS. Our results
suggest that PIK3CA hotspot mutations
do not play a major role in the
pathogenesis of LS. The lack of FGFR3
and PIK3CA mutations in LS implies
that this lesion has a different genetic
background from that of solar lentigo
and seborrheic keratosis.
Therefore, we have shown that the
absence of BRAF, FGFR3, and PIK3CA
mutations can clearly differentiate LS
from melanocytic nevi and solar lentigos.
The results furthermore indicate that LS
has a distinct yet unknown genetic basis,
which does not necessarily exclude the
proposed lentigo–nevus sequence.
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Figure 1. BRAF V600E mutation analysis. (a) Analysis of the BRAF V600E hotspot mutation using PCR
amplification of specific alleles (PASA). We analyzed lentigo simplex (LS) and melanocytic nevi (MN). For
each lesion, two PCRs were performed; one using a wild-type (wt) primer for codon 600 (top), the other
V600E mutation–specific primers (bottom). The PCR products were visualized on an agarose gel (160 bp).
Because the mutations are heterozygous, each sample displayed the BRAF wt allele. An additional band
in the second PCR, with the V600E-specific primer, indicates a V600E mutation. The LS did not show any
BRAF mutations, in contrast to some MN. (b) The frequency of the BRAF V600E mutation increased
continuously from LS to dermal melanocytic nevus. The difference between LS lesions and lentiginous/
junctional melanocytic nevi (Po0.05), as well as that between LS and all melanocytic nevus types
together (Po0.001), was significant (Fisher’s exact test). CMN, compound melanocytic nevus; DMN,
dermal melanocytic nevus; JMN, junctional melanocytic nevus; LMN, lentiginous melanocytic nevus; N,
negative control (cell lines HZT or RT4); P, positive control (cell line HT29); S, standard; W, H2O control.
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